Alpine Immune Sciences has announced that its drug povetacicept (ALPN-303) will be the subject of a late-breaking poster presentation at the International Society of Nephrology World Congress of Nephrology (WCN). WCN takes place April 13-16 in Buenos Aires, Argentina.
On April 15, James Tumlin, MD, a professor of medicine at Emory University School of Medicine and founder and chief executive officer of the NephroNet Clinical Trials Consortium, will present results from RUBY-3, a phase 1b/2a study of povetacicept in autoimmune glomerulonephritis, including IgA nephropathy (IgAN).
Povetacicept is in development for several autoimmune diseases, including IgAN and other autoimmune kidney diseases, systemic lupus erythematosus, and autoimmune cytopenias. It is a dual antagonist of the B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) cytokines, both of which play a part in the pathogenesis of autoimmune diseases through their roles in the activation, differentiation, and/or survival of B cells. Povetacicept is based on an engineered transmembrane activator and CAML interactor domain. The drug has demonstrated greater potency in preclinical studies compared with other BAFF or APRIL inhibitors alone and B-cell depletion and has demonstrated initial activity in patients with IgAN.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.